Boston Scientific Acquires BTG with its Interventional Medicine Portfolio
Shots:
- Boston acquired BTG in all stocks transaction- for ~$1.07/per share at a premium of 36.6%- with total deal value of $4.2B. The transaction is expected to close in H1’19
- The acquisition will strengthen Boston’s peripheral intervention platform with BTG’s minimally-invasive treatments like TheraSphere Y-90 radiotherapy- GALI cryoablation and EKOS Endovascular System for treatment of cancer and vascular diseases
- EKOS system is a FDA approved device used with thrombolytic agents- indicated for pulmonary embolism. TheraSphere Y-90 radiotherapy & GALI system is indicated for liver & renal cancers
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
